SCHEMBL5137871

SCHEMBL5137871

CCCCn1c(CN(Cc2ccccc2)Cc2ccc3c(c2)CCO3)cnc1-c1cccc(F)c1

nearest known ligand 0.42

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.39
KCNH2 Q12809 1/20 0.38
GSK3B P49841 3/20 0.36
MEN1 O00255 2/20 0.34
KMT2A Q03164 2/20 0.34
POLB P06746 1/20 0.34
CHRM5 P08912 3/20 0.34
CHRM1 P11229 3/20 0.34
TRPM8 Q7Z2W7 1/20 0.34
CXCR3 P49682 2/20 0.33
CHRM2 P08172 1/20 0.33
CHRM4 P08173 1/20 0.33
CHRM3 P20309 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5136708 0.93 C5AR1 (0.45) C5AR1KCNH2CHRM5CHRM1CXCR3
SCHEMBL5178967 0.92 C5AR1 (0.45) C5AR1KCNH2GSK3BPOLB
SCHEMBL5136083 0.91 C5AR1 (0.46) C5AR1KCNH2CHRM5CHRM1CXCR3
SCHEMBL5137541 0.89 CXCR3 (0.38) C5AR1KCNH2GSK3BMEN1KMT2A
SCHEMBL14415541 0.88 C5AR1 (0.52) C5AR1POLB
SCHEMBL1912862 0.88 C5AR1 (0.49) C5AR1KCNH2CHRM5CHRM1CXCR3
SCHEMBL5135014 0.86 C5AR1 (0.54) C5AR1KCNH2CHRM5CHRM1
SCHEMBL5135205 0.86 CXCR3 (0.40) C5AR1KCNH2GSK3BMEN1KMT2A
SCHEMBL4768999 0.84 C5AR1 (0.51) C5AR1POLB
SCHEMBL5134878 0.84 C5AR1 (0.55) C5AR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed